Sharps Compliance 10Q 2012 Q3 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

___________________

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2012

TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 001-34269

_______________________

SHARPS COMPLIANCE CORP.

(Exact name of registrant as specified in its charter)

Delaware	74-2657168
(State or other jurisdiction of	(I.R.S. Employer Identification No.)
incorporation or organization)

9220 Kirby Drive, Suite 500, Houston, Texas	77054
(Address of principal executive offices)	(Zip Code)

(713) 432-0300

(Registrant’s telephone number, including area code)

Indicate by check mark if the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ý No 

Indicate by check mark whether the registrant is a large accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "large accelerated filer", "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Securities Exchange Act of 1934.


Large Accelerated Filer o		Accelerated Filer ý		Non-accelerated Filer o (Do not check if a smaller reporting company)		Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act). Yes o No ý

As of May 1, 2012, there were 15,179,187 outstanding shares of the Registrant's common stock, par value $0.01 per share.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

PART I	FINANCIAL INFORMATION	PAGE

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets as of March 31, 2012 and June 30, 2011	3

	Condensed Consolidated Statements of Operations for the three months ended March 31, 2012 and 2011	4

	Condensed Consolidated Statements of Operations for the nine months ended March 31, 2012 and 2011	5

	Condensed Consolidated Statements of Stockholders’ Equity for the nine months ended March 31, 2012 and year ended June 30, 2011	6

	Condensed Consolidated Statements of Cash Flows for the nine months ended March 31, 2012 and 2011	7

	Notes to Condensed Consolidated Financial Statements	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	21

tem 4.	Controls and Procedures	21

Part II	OTHER INFORMATION

Item 1.	Legal Proceedings	21

Item 1A.	Risk Factors	21

Item 6.	Exhibits	22

	SIGNATURES	23

PART IFINANCIAL INFORMATION

ITEM 1.FINANCIAL STATEMENTS

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)


	March 31,			June 30,
	2012			2011
	(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	16,582		$	18,280
Accounts receivable, net of allowance for doubtful accounts of $28 and
$26, respectively		3,951			3,065
Inventory		2,456			1,770
Prepaid and other current assets		896			857
Deferred income taxes		275			203
TOTAL CURRENT ASSETS		24,160			24,175

PROPERTY, PLANT AND EQUIPMENT, net		4,892			5,350

DEFERRED INCOME TAXES, non-current		1,241			748

INTANGIBLE ASSETS, net of accumulated amortization of $249 and
$227, respectively		397			325

TOTAL ASSETS	$	30,690		$	30,598

LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES			��
Accounts payable	$	1,255		$	965
Accrued liabilities		1,195			1,260
Deferred revenue		1,933			1,724
TOTAL CURRENT LIABILITIES		4,383			3,949

LONG-TERM DEFERRED REVENUE		354			401

OTHER LONG-TERM LIABILITIES		218			383

TOTAL LIABILITIES		4,955			4,733

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS' EQUITY
Common stock, $0.01 par value per share; 20,000 shares authorized;
15,179 and 15,053 shares issued and outstanding, respectively		152			151
Additional paid-in capital		22,288			21,602
Retained earnings		3,295			4,112
TOTAL STOCKHOLDERS' EQUITY		25,735			25,865

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	30,690		$	30,598

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per-share data)

	Three-Months
	Ended March 31,
	2012			2011
	(Unaudited)

REVENUES	$	5,291		$	4,518

COSTS AND EXPENSES
Cost of revenues		3,766			3,109
Selling, general and administrative		2,218			2,438
Depreciation and amortization		115			89
TOTAL COSTS AND EXPENSES		6,099			5,636

OPERATING LOSS		(808	)		(1,118	)

OTHER INCOME
Other income		8			14
TOTAL OTHER INCOME		8			14

LOSS BEFORE INCOME TAXES		(800	)		(1,104	)

INCOME TAX EXPENSE (BENEFIT )
Current		63			81
Deferred		(343	)		(526	)
TOTAL INCOME TAX BENEFIT		(280	)		(445	)


NET LOSS	$	(520	)	$	(659	)

NET LOSS PER COMMON SHARE
Basic	$	(0.03	)	$	(0.04	)

Diluted	$	(0.03	)	$	(0.04	)

WEIGHTED AVERAGE SHARES USED IN COMPUTING
NET LOSS PER COMMON SHARE:

Basic		15,111			14,948
Diluted		15,111			14,948

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per-share data)

	Nine-Months
	Ended March 31,
	2012			2011
	(Unaudited)

REVENUES	$	17,246		$	14,362

COSTS AND EXPENSES
Cost of revenues		11,755			9,915
Selling, general and administrative		6,425			7,152
Special charge		-			570
Depreciation and amortization		338			265
TOTAL COSTS AND EXPENSES		18,518			17,902

OPERATING LOSS		(1,272	)		(3,540	)

OTHER INCOME
Other income		14			42
TOTAL OTHER INCOME		14			42

LOSS BEFORE INCOME TAXES		(1,258	)		(3,498	)

INCOME TAX EXPENSE (BENEFIT)
Current		63			(1,261	)
Deferred		(504	)		26
TOTAL INCOME TAX BENEFIT		(441	)		(1,235	)


NET LOSS	$	(817	)	$	(2,263	)

NET LOSS PER COMMON SHARE
Basic	$	(0.05	)	$	(0.15	)

Diluted	$	(0.05	)	$	(0.15	)

WEIGHTED AVERAGE SHARES USED IN COMPUTING NET
LOSS PER COMMON SHARE:

Basic		15,084			14,925
Diluted		15,084			14,925

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands, except share data)


					Additional						Total
	Common Stock				Paid-in			Retained			Stockholders'
	Shares		Amount		Capital			Earnings			Equity

Balances, June 30, 2010		14,891,754	$	149	$	19,705		$	7,087		$	26,941

Exercise of stock options		62,500		1		48			-			49

Stock-based
compensation		-		-		871			-			871

Issuance of restricted stock		99,062		1		(1	)		-			-

Excess tax benefit from
stock-based award activity		-		-		979			-			979

Net Loss		-		-		-			(2,975	)		(2,975	)

Balances, June 30, 2011		15,053,316		151		21,602			4,112			25,865

Exercise of stock options*		79,751		1		56			-			57

Stock-based
compensation*		-		-		569			-			569

Issuance of restricted stock*		46,120		-		-			-			-

Excess tax benefit from
stock-based award activity*		-		-		61			-			61

Net Loss*		-		-		-			(817	)		(817	)

Balances, March 31, 2012*		15,179,187	$	152	$	22,288		$	3,295		$	25,735

* unaudited

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

	Nine-Months Ended
	March 31,
	2012			2011
	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(817	)	$	(2,263	)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization		829			751
Loss on disposal of property, plant and equipment		13			-
Stock-based compensation expense		569			686
Excess tax benefits from stock-based award activity		(61	)		(939	)
Deferred tax (benefit) expense		(504	)		26
Changes in operating assets and liabilities:
Increase in accounts receivable		(886	)		(109	)
Increase in inventory		(686	)		(341	)
Increase in prepaid and other current assets		(39	)		(382	)
Increase in accounts payable and accrued liabilities		60			1,072
Increase in deferred revenue		162			6
NET CASH USED IN OPERATING ACTIVITIES		(1,360	)		(1,493	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(362	)		(556	)
Additions to intangible assets		(94	)		(125	)
NET CASH USED IN INVESTING ACTIVITIES		(456	)		(681	)

CASH FLOWS FROM FINANCING ACTIVITIES
Excess tax benefits from stock-based award activity		61			939
Proceeds from exercise of stock options		57			3
NET CASH PROVIDED BY FINANCING ACTIVITIES		118			942

NET DECREASE IN CASH AND CASH EQUIVALENTS		(1,698	)		(1,232	)

CASH AND CASH EQUIVALENTS, beginning of period		18,280			18,068

CASH AND CASH EQUIVALENTS, end of period	$	16,582		$	16,836

The accompanying notes are an integral part of these condensed consolidated financial statements.

SHARPS COMPLIANCE CORP. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 - ORGANIZATION AND BACKGROUND

The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com, Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.) and Sharps Safety, Inc. (collectively, “Sharps”, “We” or the “Company”). All significant intercompany accounts and transactions have been eliminated upon consolidation.

NOTE 2 - BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of March 31, 2012, the results of its operations and cash flows for the three and nine months ended March 31, 2012 and 2011 and stockholders’ equity for the year ended June 30, 2011 and nine months ended March 31, 2012. The results of operations for the three and nine months ended March 31, 2012 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2012. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2011.

NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES

REVENUE RECOGNITION

The Company recognizes revenue from product sales when goods are shipped or delivered, and title and risk of loss pass to the customer except for those sales via multiple-deliverable arrangements. Provisions for certain rebates, product returns and discounts to customers are accounted for as reductions in sales in the same period the related sales are recorded.

Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.

The Company recognizes revenue in accordance with guidance on revenue recognition of multiple-deliverable revenue arrangements. On July 1, 2010, the Company adopted ASU No. 2009-13 which further clarified guidance on revenue recognition for multiple-deliverable revenue arrangements, changing the way the Company allocates arrangement consideration to the separate units of accounting. Under this guidance, certain products offered by the Company have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System™ (formerly the Sharps Disposal by Mail Systems®) and various TakeAway Environmental Return Systems™ referred to as “Mailbacks” and Sharps® Pump and Asset Return Boxes, referred to as “Pump Returns”) and can consist of up to three separate elements, or units of measure, as follows: (1) the sale of the compliance and container system, (2) return transportation and (3) treatment service.

Prior to July 1, 2010, the individual fair value of the transportation and treatment services were determined by the sales price of the service offered by third parties, with the fair value of the compliance and container being the residual value. Beginning July 1, 2010, under the relative selling price methodology, an estimated selling price is determined for all deliverables that qualify for separate units of accounting. The actual consideration received in a multiple-deliverable arrangement is then allocated to the units based on their relative sales price. Because an estimated selling price must be set for each unit, the residual method used previously by the Company to allocate consideration to the compliance and container system is no longer allowed. The selling price for the transportation revenue and the treatment revenue, which utilizes third party evidence, did not change from the prior method. The Company estimates the selling price of the compliance and container system based on the product and services provided including compliance with local, state and Federal laws, adherence to stringent manufacturing and testing requirements, safety to the patient and the community as well as storage and containment capabilities.

mailed or delivered by an alternative logistics provider to the Company’s facility. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.

ACCOUNTS RECEIVABLE

Accounts receivable consist primarily of amounts due to us from our normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the expected uncollectibility of accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company has determined that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.

NOTE 4 – RECENTLY ISSUED ACCOUNTING STANDARDS

There are no recently issued accounting pronouncements that impact the Company’s condensed consolidated financial statements as of March 31, 2012.

NOTE 5 - INCOME TAXES

The Company’s effective tax rate for the nine months ended March 31, 2012 was 35.1% compared to 35.3% for the nine months ended March 31, 2011 and 33.8% for the fiscal year ended June 30, 2011. The Company received a Federal Tax refund of $0.5 million in April 2012 which related to the carryback of losses incurred thru June 30, 2011. This amount is included in Prepaid and Other Current Assets as of March 31, 2012.

NOTE 6 - NOTES PAYABLE AND LONG-TERM DEBT

The Company’s Credit Agreement with Wells Fargo Bank, National Association provides for a two-year, $5.0 million line of credit facility, the proceeds of which may be utilized for: (i) working capital, (ii) capital expenditures, (iii) letters of credit (up to $500,000), (iv) acquisitions (up to $1,000,000) and (v) general corporate purposes. As of March 31, 2012, the Company had no outstanding borrowings, $106 thousand in letters of credit outstanding, and $4.9 million of credit available.

Indebtedness under the Credit Agreement is secured by substantially all of the Company’s assets. Borrowings bear interest at either (i) a fluctuating rate per annum equal to LIBOR plus a margin of 250 basis points or (ii) at the Company’s option, a fixed rate for a 30, 60, or 90 day period set at the option date’s LIBOR plus a margin of 250 basis points. Any outstanding revolving loans, and accrued and unpaid interest, will be due and payable on July 15, 2012, the maturity date of the Credit Agreement. The Company pays a fee of 0.2% per annum on the unused amount of the line of credit. The Company estimates that the interest rate applicable to the borrowings under the Credit Agreement would be approximately 3.0% as of March 31, 2012.

The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a minimum level of tangible net worth of $21 million and not exceed a ratio of liabilities to tangible net worth of 1.0 to 1.0. As of March 31, 2012, the Company is in compliance with all financial covenants. The Credit Agreement also contains customary events of default. Upon the occurrence of an event of default that remains uncured after any applicable cure period, the lenders’ commitment to make further loans may terminate and the Company may be required to make immediate repayment of all indebtedness to the lenders. The Credit Agreement expires on July 15, 2012. The Company is in current discussions with the lender and expects to extend the Credit Agreement with similar terms.

NOTE 7 – STOCK-BASED COMPENSATION

Stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity grant). Total stock-based compensation for the three months ended March 31, 2012 and 2011 was $193 thousand ($15 thousand included in cost of revenues and $178 thousand included in general and administrative expense in the Company’s condensed consolidated statement of operations) and $179 thousand ($5 thousand included in cost of revenues and $174 thousand included in general and administrative expense in the Company’s condensed consolidated statement of operations), respectively. Total stock-based compensation for the nine months ended March 31, 2012 and 2011 was $569 thousand ($53 thousand included in cost of revenues and $516 thousand included in general and administrative expense in the Company’s condensed consolidated statement of operations) and $686 thousand ($50 thousand included in cost of revenues and

$636 thousand included in general and administrative expense in the Company’s condensed consolidated statement of operations), respectively.

Reductions in taxes payable resulting from tax deductions that exceed the recognized tax benefit associated with compensation expense (excess tax benefits) are classified as financing cash flows and as an increase to additional paid in capital. The Company’s excess tax benefits included in its cash flows from financing activities for the nine months ended March 31, 2012 and 2011 was $61 thousand and $939 thousand, respectively.

In conjunction with the retirement and separation agreement of Dr. Burton Kunik, effective September 30, 2010, the Company recognized an additional $73 thousand in stock-based compensation expense which is included in the Special Charge on the accompanying statement of operations for the nine months ended March 31, 2011.

NOTE 8 - EARNINGS PER SHARE

Earnings per share are measured at two levels: basic per share and diluted per share. Basic per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted per share is computed by dividing net income by the weighted average number of common shares after considering the additional dilution related to common stock options and restricted stock. In computing diluted earnings per share, the outstanding common stock options are considered dilutive using the treasury stock method. Vested restricted shares are included in basic common shares outstanding, and unvested restricted shares are included in the diluted common shares outstanding, if the effect is dilutive.

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):

	Three-Months Ended						Nine-Months Ended
	March 31,						March 31,
	2012			2011			2012			2011
	(Unaudited)						(Unaudited)

Net loss, as reported	$	(520	)	$	(659	)	$	(817	)	$	(2,263	)

Weighted average common shares outstanding		15,111			14,948			15,084			14,925
Effect of dilutive stock options		-			-			-			-
Weighted average diluted common shares outstanding		15,111			14,948			15,084			14,925

Net loss per common share
Basic	$	(0.03	)	$	(0.04	)	$	(0.05	)	$	(0.15	)
Diluted	$	(0.03	)	$	(0.04	)	$	(0.05	)	$	(0.15	)

Employee stock options excluded from computation
of dilutive income per share amounts because their
effect would be anti-dilutive		833			390			833			390

NOTE 9 - EQUITY TRANSACTIONS

During the three and nine months ended March 31, 2012 and 2011, stock options to purchase shares of the Company’s common stock were exercised as follows:


	Three-Months Ended				Nine-Months Ended
	March 31,				March 31,
	2012		2011		2012		2011
	(Unaudited)				(Unaudited)

Options exercised		65,648		3,000		79,751		5,000
Proceeds (in thousands)	$	43	$	2	$	56	$	3
Average exercise price per share	$	0.66	$	0.60	$	0.71	$	0.70

As of March 31, 2012, there was $833 thousand of stock option and restricted stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 2.27 years.

NOTE 10 – INVENTORY

The components of inventory are as follows (in thousands):

	March 31,		June 30,
	2012		2011
	(Unaudited)
Raw materials	$	1,276	$	790
Finished goods		1,180		980
Total	$	2,456	$	1,770

NOTE 11 – FAIR VALUE OF FINANCIAL INSTRUMENTS

The Company considers the fair value of all financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, not to be materially different from their carrying values at year-end due to their short-term nature.

ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

INFORMATION REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains certain forward-looking statements and information relating to the Company and its subsidiaries that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. When used in this report, the words “anticipate”, “believe”, “expect”, “estimate”, “project” and “intend” and words or phrases of similar import, as they relate to the Company or its subsidiaries or Company management, are intended to identify forward-looking statements. Such statements reflect the current risks, uncertainties and assumptions related to certain factors, including without limitations, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein. Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, expected, estimated or intended. The Company does not intend to update these forward-looking statements.

GENERAL

Sharps Compliance Corp. is a leading full-service provider of cost-effective solutions designed for the proper management of for medical waste, used healthcare materials and unused dispensed medications. Our solutions facilitate the proper treatment of numerous types of medical waste, used healthcare materials and unused dispensed medications, including hypodermic needles, lancets and other devices or objects used to puncture or lacerate the skin, or sharps, and unused dispensed prescription and over-the-counter drugs and medications. We serve customers in multiple markets such as home health care, retail clinics and immunizing pharmacies, pharmaceutical manufacturers, professional offices (physicians, dentists and veterinarians), hospitality (including assisted living facilities, hotels, motels and restaurants), government (federal, state and local), consumers, commercial, industrial and agriculture, and distributors to many of the aforementioned markets. We assist our customers in determining which of our distinct solution offerings best fit their needs for the collection, storage, return transportation and treatment of their or their patients’ medical waste and unused dispensed medications. Our differentiated approach provides our customers the flexibility to return and ultimately properly treat their or their patients’ medical waste or unused dispensed medications through pre-paid mail services primarily through the United States Postal Service (“USPS”). Furthermore, we provide comprehensive tracking and reporting tools that enable our customers to meet complex medical waste disposal and unused dispensed patient medication compliance requirements. We believe the fully-integrated nature of our operations is a key factor leading to our success and continued recurring revenue growth. The Company’s primary solutions include Sharps Recovery System™ (formerly Sharps Disposal by Mail System®), TakeAway Recovery System™, Complete Needle™ Collection and Disposal System, TakeAway Environmental Return System™, Rx TakeAway Recovery and Reporting System™, Sharps Recovery System™ Needle Collection and Mailback Disposal, Sharps® MWMS™, Sharps Secure® Needle Collection and Containment System, Pitch-It IV™ Poles, Trip LesSystem®, Sharps® Pump and Asset Return System, IsoWash® Linen Recovery System and Biohazard Spill Clean-Up Kit and Disposal System.

RESULTS OF OPERATIONS

The following analyzes changes in the consolidated operating results and financial condition of the Company during the three and nine months ended March 31, 2012 and 2011. The following table sets forth, for the periods indicated, certain items from the Company's Condensed Consolidated Statements of Operations, dollars in thousands and percentages expressed as a percentage of revenue:

	Three-Months Ended March 31,												Nine-Months Ended March 31,
	2012			%			2011			%			2012			%			2011			%
	(Unaudited)												(Unaudited)

Revenues	$	5,291			100.0	%	$	4,518			100.0	%	$	17,246			100.0	%	$	14,362			100.0	%

Cost of revenues		3,766			71.2	%		3,109			68.8	%		11,755			68.2	%		9,915			69.0	%
Gross profit		1,525			28.8	%		1,409			31.2	%		5,491			31.8	%		4,447			31.0	%

SG&A expense		2,218			41.9	%		2,438			54.0	%		6,425			37.3	%		7,152			49.8	%
Special charge		-			0.0	%		-			0.0	%		-			0.0	%		570			4.0	%
Depreciation and amortization		115			2.2	%		89			2.0	%		338			2.0	%		265			1.8	%

Operating loss		(808	)		(15.3	%)		(1,118	)		(24.7	%)		(1,272	)		(7.4	%)		(3,540	)		(24.6	%)
																		��
Other income		8			0.2	%		14			0.3	%		14			0.1	%		42			0.3	%

Loss before income taxes	$	(800	)		(15.1	%)	$	(1,104	)		(24.4	%)	$	(1,258	)		(7.3	%)	$	(3,498	)		(24.4	%)
Income tax benefit		(280	)		(5.3	%)		(445	)		(9.8	%)		(441	)		(2.6	%)		(1,235	)		(8.6	%)
Net loss	$	(520	)		(9.8	%)	$	(659	)		(14.6	%)	$	(817	)		(4.7	%)	$	(2,263	)		(15.8	%)

Net loss per share
Basic	$	(0.03	)				$	(0.04	)				$	(0.05	)				$	(0.15	)
Diluted	$	(0.03	)				$	(0.04	)				$	(0.05	)				$	(0.15	)

Weighted Average Shares Outstanding
Basic		15,111						14,948						15,084						14,925
Diluted		15,111						14,948						15,084						14,925

THREE MONTHS ENDED MARCH 31, 2012 AS COMPARED TO THREE MONTHS ENDED MARCH 31, 2011

Total revenues for the three months ended March 31, 2012 of $5.3 million increased by $0.8 million, or 17.1%, over the total revenues for the three months ended March 31, 2011 of $4.5 million. Billings by market are as follows (in thousands):

	Three-Months Ended March 31,
	(Unaudited)
	2012			2011		Variance

BILLINGS BY MARKET:
Home Health Care	$	1,478		$	1,615	$	(137	)
Retail		1,399			810		589
Pharmaceutical		870			72		798
Professional		815			439		376
Assisted Living / Hospitality		368			373		(5	)
U.S Government Contract		241			608		(367	)
Core Government		110			226		(116	)
Other		189			310		(121	)
Subtotal		5,470			4,453		1,017
GAAP Adjustment *		(179	)		65		(244	)
Revenue Reported	$	5,291		$	4,518	$	773

*Represents the net impact of the revenue recognition adjustment required to arrive at reported generally accepted accounting principles (“GAAP”) revenue. Customer billings include all invoiced amounts associated with products shipped during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales and (ii) recognition of certain revenue associated with products returned for treatment and destruction. The difference between customer billings and GAAP revenue is reflected in the Company’s balance sheet as deferred revenue. See Note 3 “Revenue Recognition” in “Notes to Condensed Consolidated Financial Statements”.

This quarterly report on Form 10-Q contains certain financial information not dervied in accordance with GAAP, including customer billings information. The Company believes this information is useful to investors and other interested parties as customer billings represents all invoiced amounts associated with products shipped during the period reported. Such information should not be considered as a substitute for any measures derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included above.

The increase in revenues is primarily attributable to increased billings in the Pharmaceutical ($0.8 million), Retail ($0.6 million) and Professional ($0.4 million) markets. The increase in billings was partially offset by decreased billings in the U.S. Government contract ($0.4 million), Home Health Care ($0.1 million) and Core Government ($0.1 million) markets. The increase in the Pharmaceutical market billings is due to the continued roll-out of two new programs and initial launch during the quarter of a third new patient support program. The programs include the direct fulfillment of the Sharps Recovery System® to the pharmaceutical manufacturers’ program participants which provides the proper containment, return and treatment of the needles or injection devices utilized in therapy. The increase in the Retail market is primarily due to a strong level of orders by the retail pharmacies in advance of the 2012 flu shot season as well as increased immunizations administered in the retail setting. The percentage of flu shots and other injections administered in the retail pharmacy setting continues to grow as retailers are moving aggressively to provide more health care services to their customers. Partially offsetting this increase was prior year sales to a large national retail pharmacy and two food and drug chains which selected the Company’s TakeAway™ Environmental Return System™ envelope solution to feature in their pharmacies across the nation. The increase in the Professional market was a direct result of the Company’s targeted telemarketing activities,

e-commerce focused website, trade show participation and internet-based promotional activities to educate doctors, dentists and veterinarians on the significant cost advantage and the convenience of the Sharps Recovery System™ over the traditional pick-up service. U.S. Government contract billings are associated with the Company’s contract with a major U.S. government agency announced in February 2009.The decrease in the U.S. Government contract market billings is due to the non-renewal of the third option year for the maintenance phase of the contract. In January 2012, the Company was notified by a department of the U. S. Government, acting on behalf of the Division of Strategic National Stockpile (“DSNS”), that the maintenance contract would not be renewed for the third option year (beginning February 1, 2012). The decrease in billings in the Home Health Care market was primarily due to timing of sales to home health care related distributors addressing the growing trend of patient volumes in the home health care industry. The level of Core Government market billings reflects the completion of the VA Pilot Program. The VA has assigned an internal representative to evaluate the pilot and what a potential nationwide rollout would entail. Revenue was negatively impacted by an increase in the GAAP adjustment of $0.2 million primarily related to the mix of products sold in the prior year and the impact of deferrals.

Cost of revenues for the three months ended March 31, 2012 of $3.8 million was 71.2% of revenues. Cost of revenues for the three months ended March 31, 2011 of $3.1 million was 68.8% of revenues. The lower gross margin for the quarter ended March 31, 2012 of 28.8% (versus 31.2% for the quarter ended March 31, 2011) was due to facility costs launched in 2009 in conjunction with the U.S. government contract that was terminated as of January 31, 2012.

Selling, general and administrative (“SG&A”) expenses for the three months ended March 31, 2012 of $2.2 million, decreased by $0.2 million, from SG&A expenses of $2.4 million for the three months ended March 31, 2011. The decrease in SG&A is primarily due to decreased professional expenses of $0.3 million (primarily due to regulatory and consulting fees, legal fees, audit and related fees and recruiting fees). The decrease was offset by increased sales and marketing related expenses.

The Company generated operating loss of $0.8 million for the three months ended March 31, 2012 compared to an operating loss of $1.1 million for the three months ended March 31, 2011. The operating margin was (15.3%) for the three months ended March 31, 2012 compared to (24.7%) for the three months ended March 31, 2011. The improvement in operating loss is a result of the higher sales volume as well as strong cost discipline and focused use of resources on targeted markets primarily Retail, Pharmaceutical, Professional and Core Government markets (discussed above).

The Company generated loss before tax of $0.8 million for the three months ended March 31, 2012 versus a loss before tax of $1.1 million for the three months ended March 31, 2011. The improvement in the loss before tax is a result of the increase in operating income (discussed above).

The Company’s effective tax rate for the three months ended March 31, 2012 was 35.0% compared to 40.3% for the three months ended March 31, 2011 and 33.8% for the fiscal year ended June 30, 2011.

The Company generated a net loss of $0.5 million for the three months ended March 31, 2012 compared to a net loss of $0.7 million for the three months ended March 31, 2011. The improvement is a result of lower operating loss (discussed above).

The Company reported diluted loss per share of ($0.03) for the three months ended March 31, 2012 versus diluted loss per share of ($0.04) for the three months ended March 31, 2011. The improvement in diluted earnings per share is a result of a lower net loss in the current quarter (discussed above).

NINE MONTHS ENDED MARCH 31, 2012 AS COMPARED TO NINE MONTHS ENDED MARCH 31, 2011

Total revenues for the nine months ended March 31, 2012 of $17.2 million increased by $2.9 million, or 20.1%, over the total revenues for the nine months ended March 31, 2011 of $14.4 million. Billings by market are as follows (in thousands):

	Nine-Months Ended March 31,
	(Unaudited)
	2012			2011		Variance

BILLINGS BY MARKET:
Home Health Care	$	4,985		$	5,270	$	(285	)
Retail		4,425			3,473		952
Pharmaceutical		1,849			249		1,600
Professional		2,237			1,430		807
Assisted Living / Hospitality		937			946		(9	)
U.S. Government Contract		1,685			1,367		318
Core Government		325			516		(191	)
Other		892			990		(98	)
Subtotal		17,335			14,241		3,094
GAAP Adjustment *		(89	)		121		(210	)
Revenue Reported	$	17,246		$	14,362	$	2,884

This quarterly report on Form 10-Q contains certain year-to-date financial information not derived in accordance with GAAP, including customer billings information. The Company believes this information is useful to investors and other interested parties as customer billings represents all invoiced amounts associated with products shipped during the period reported. Such information should not be considered as a substitute for any measures derived in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included above.

The increase in revenues is primarily attributable to increased billings in the Pharmaceutical ($1.6 million), Retail ($1.0 million), Professional ($0.8 million) and U.S. Government Contract ($0.3 million) markets. These increases in billings were partially offset by decreased billings in the Home Health Care ($0.3 million) and Core Government ($0.2 million) markets. The increase in the Pharmaceutical market billings is due to the timing of customer orders including resupply orders for existing patient support programs and the launch of three new patient support programs announced in August and October 2011. The programs include the direct fulfillment of the Sharps Recovery System® to the pharmaceutical manufacturers’ program participants which provides the proper containment, return and treatment of the needles or injection devices utilized in therapy. The increase in the Retail market is primarily due to sales from the initial fill of the Complete Needle™ Collection & Disposal System in the country’s largest drugstore chain (totaling $0.5 million), a strong 2011 flu shot season, orders in advance of the 2012 flu shot season and more immunizations administered in the retail setting. Partially offsetting this increase was prior year sales of $1.3 million related to the initial orders of the Company’s TakeAway™ Environmental Return System™ envelope solution by two large retail pharmacy chains and several food and drug chains to address growing concerns regarding the hazards of unused medications in the home and environment. The increase in the Professional market was a direct result of the Company’s targeted telemarketing activities, new website and corresponding promotional activities to educate doctors, dentists and veterinarians on the significant cost advantage and the convenience of the Sharps Recovery System™ over the traditional pick-up service. U.S. Government Contract billings are associated with the Company’s contract with a major U.S. government agency announced in February 2009.The increase in the U.S. Government contract market billings is due to the beginning of the second option year, which included a higher payment for increased maintenance service fees than the first option year partially offset by the non-renewal of the third option year beginning February 1, 2012 (discussed above). The decrease in billings in the Home Health Care market was primarily due to timing of sales to home health care related distributors addressing the growing trend of patient volumes in the home health care industry. The level of Core Government market billings reflects the completion of the VA Pilot Program. The VA has assigned an internal representative to evaluate the pilot and what a potential nationwide rollout would entail. Revenue was negatively impacted by an increase in the GAAP adjustment of $0.2 million primarily related to the mix of products sold in the prior year and the impact of deferrals.

Cost of revenues for the nine months ended March 31, 2012 of $11.8 million was 68.2% of revenues. Cost of revenues for the nine months ended March 31, 2011 of $9.9 million was 69.0% of revenue. The higher gross margin for the nine months ended March 31, 2012 of 31.8% (versus 31.0% for the nine months ended March 31, 2011) was due to the leverage inherent in the business due to increased sales volume offset by unscheduled maintenance and repairs at the Company’s treatment facility and up-front costs related to the initial rollout of the Complete Needle™ Collection & Disposal System as well as facility costs launched in 2009 in conjunction with the U.S. government contract that was terminated as of January 31, 2012.

Selling, general and administrative (“SG&A”) expenses for the nine months ended March 31, 2012 of $6.4 million, decreased by $0.8 million, from SG&A expenses of $7.2 million for the nine months ended March 31, 2011. The decrease in SG&A is primarily due to (i) lower professional fees of $0.4 million (primarily due to regulatory and consulting fees, legal fees and other sales-related consulting fees), (ii) lower compensation and benefit expense including payroll tax of $0.2 million (primarily due to timing of employee hires and terminations) and (iii) lower miscellaneous expense of $0.2 million (primarily related lower to recruiting fees). The decrease was partially offset by increased sales and marketing related expense of $0.1 million.

During the first quarter of fiscal year 2011, the Company recorded a special charge of $0.6 million on a pre-tax basis, or $0.02 per diluted loss per share, which represents expenses incurred with the retirement of the Company’s former Chief Executive Officer, Dr. Burton Kunik. The special charge consists of (i) severance-related items totaling $0.5 million and (ii) non-cash stock-based compensation expense of $0.1 million (resulting from accelerated vesting of stock option awards). The Company paid Dr. Kunik $0.1 million in September 2010 and $0.4 million in April 2011 related to the expenses noted above.

The Company generated an operating loss of $1.3 million for the nine months ended March 31, 2012 compared to an operating loss of $3.5 million for the nine months ended March 31, 2011. The operating margin was (7.4%) for the nine months ended March 31, 2012 compared to (24.6%) for the nine months ended March 31, 2011. The improvement in operating loss is a result of the higher sales volume as well as strong cost discipline and focused use of resources on targeted markets primarily Retail, Pharmaceutical, Professional and Core Government markets (discussed above).

The Company generated a loss before tax of $1.3 million for the nine months ended March 31, 2012 versus a loss before tax of $3.5 million for the nine months ended March 31, 2011. The improvement in loss before tax is a result of a lower operating loss (discussed above).

The Company’s effective tax rate for the nine months ended March 31, 2012 was 35.1% compared to 35.3% for the nine months ended March 31, 2011 and 33.8% for the fiscal year ended June 30, 2011.

The Company generated a net loss of $0.8 million for the nine months ended March 31, 2012 compared to a net loss of $2.3 million for the nine months ended March 31, 2011. The improvement is result of a lower operating loss (discussed above).

The Company reported diluted loss per share of ($0.05) for the nine months ended March 31, 2012 versus diluted loss per share of ($0.15) for the nine months ended March 31, 2011. The improvement in diluted earnings per share is a result of a lower net loss (discussed above).

PROSPECTS FOR THE FUTURE

The Company continues to take advantage of the many opportunities in the markets served as professional offices, retail pharmacies, communities, consumers, pharmaceutical manufacturers, government agencies, health care facilities, individual self-injectors and commercial organizations become more aware of the need for the proper treatment of medical sharps waste, used healthcare materials and unused dispensed medications as well as alternatives to traditional methods of disposal.

Recent data from the Human Capital Management Services Group indicates that the number of used needles improperly disposed of outside the large healthcare setting and into the solid waste system has tripled over the past ten years to 7.8 billion each year and the number of self-injectors in the country has increased to 13.5 million over the same period. The Company estimates that it would require over 80 million Sharps Recovery System™ (formerly Sharps Disposal by Mail System®) products to properly dispose of all such syringes, which would equate to a market opportunity of over $2 billion.

There are an estimated 800,000 doctors, dentists, veterinarians, clinics, tattoo parlors and other businesses in the country that generate smaller quantities of medical waste, including used syringes. These offices and facilities, which must demonstrate proper management of their medical waste, comprise a market opportunity of approximately $600 million, based on estimates of using our solution offerings rather than the traditional pick-up service in what we characterize as a regulated market.

Additionally, an estimated 40% of the four billion dispensed medication prescriptions go unused every year in the United States generating an estimated 200 million pounds of unused medication waste. The Company estimated the market opportunity for the proper recovery and management of the unused medications to be at least $1 billion per year.

The Company continues to develop new solution offerings including the Complete Needle™ Collection and Disposal System (designed for the traditional under-served home self-injector), the TakeAway line of products for unused medications (including TakeAway Environmental Return System™ ), the Medical/Professional TakeAway Recovery System™ and the RX TakeAway Recovery and Reporting System which offers the collection, storage, audit, witnessed treatment and documentation of unused medications such as flu vaccines, Tamiflu, and Relenza. These innovative product and service offerings allow us to gain further sales from existing customers as well as gain new customers who have a need for more comprehensive products. The Company continues to develop solution offerings designed to facilitate the proper and cost effective solutions for management of medical waste, used healthcare materials and unused dispensed medication to better serve our customers and the environment. The Company believes its future growth will be driven by, among other items: (i) the convergence of issues regarding the environment, the cost of health care and changes in our health care delivery system and cost-savings initiatives which influence the decision process of our customers, (ii) the effects of the Company’s extensive multi-layered marketing and awareness efforts and (iii) the Company’s leadership position in the development and sales of products and services designed for the proper and cost effective solutions for management of medical waste, used healthcare materials and unused dispensed.

In August 2011, the Company introduced the Complete Needle™ Collection and Disposal System which is focused on the traditional under-served home self-injector required to regularly use needles or syringes for their health and well-being, such as people with diabetes. The Complete Needle™ Collection and Disposal System is actually two offerings in one. First, the product provides the individual self-injector with a reasonably priced containment solution designed to protect self-injectors and their family members. Second, the product includes an optional disposal feature utilizing the USPS designed to protect the individual’s community, solid waste workers and the environment. The solution offers significant convenience as it utilizes the same delivery channel, the retail pharmacy, that the self-injector typically uses to obtain medications, for example, insulin, and needles or syringes. The solution is also designed to enhance the interaction between the pharmacist and the individual thereby creating counseling opportunities and possibly better treatment outcomes.

The Company continues to add full-service, patient support programs with major pharmaceutical manufacturers whereby we provide a customized Sharps Recovery System™ (formerly Sharps Disposal by Mail System®) along with fulfillment, inventory management, storage and data services, as well as provide critical patient usage data that assists the manufacturers in assessing drug effectiveness and compliance.

In January 2010, the Company announced a pilot program with the United States Department of Veterans Affairs (“VA”). The program was launched within the VA Capitol Health Care Network (“Veterans Integrated Service Network 5” or “VISN 5”), which provided quality health care for eligible veterans in Maryland and portions of Virginia, West Virginia, and Pennsylvania, as well as the District of Columbia. The pilot allowed each of the participating medical centers within the VISN 5 region, both inpatient and outpatient, to provide the Sharps Recovery System™ (formerly known as the Sharps® Disposal By Mail System®) and the TakeAway Environmental Return System™ solutions to their patients. Since its original launch, the pilot program expanded to include eight VISN’s (encompassing twenty-two states plus the District of Columbia). There are a total of twenty-three VISN’s in the VA System. The VISN network is part of the Veterans Health Administration which encompasses the largest integrated health care system in the United States, consisting of 153 medical centers, in addition to numerous community based outpatient clinics, community living centers and Vet Centers.

Together these health care facilities provide comprehensive care to over 5.5 million Veterans each year. The VA Pilot, which was completed in the first quarter of fiscal year 2012, was conducted in 22 states plus the District of Columbia. The VA has assigned an internal representative to evaluate the pilot and what a potential nationwide rollout would entail.

In February 2009, the Company launched Sharps®MWMS™, a Medical Waste Management System (“MWMS”), which is a comprehensive medical waste and dispensed medication solution which includes an array of products and services necessary to effectively collect, store and treat medical waste and unused dispensed medication outside of the hospital or large health care facility setting. In connection with the launch in 2009, the Company signed a five year contract (one year, plus four option years) with a major U.S. government agency for a $40 million program to provide our comprehensive Medical Waste Management System™, or Sharps®MWMS™, which is a rapid-deployment solution offering designed to provide medical waste collection, storage and treatment in the event of natural disasters, pandemics, man-made disasters, or other national emergencies. Sharps®MWMS™ is unique in that the solution also offers warehousing, inventory management, training, data and other services necessary to provide a comprehensive solution. We received a purchase order for $28.5 million ($6.0 million of which was recognized in fiscal year 2009, and $22.5 million was recognized in the first half of fiscal year 2010). In January 2010, the Company was awarded the first option year (ending January 31, 2011) valued at approximately $1.6 million which was recognized from February 1, 2010 through January 31, 2011. In January 2011, we were awarded the second option year (ending January 31, 2012) valued at approximately $3.0 million and was recognized from February 1, 2011 through January 31, 2012. The remaining two option years were expected to be approximately $3.0 million per contract year. On January 13, 2012, the Company was notified by a department of the U. S. Government, acting on behalf of the Division of Strategic National Stockpile (“DSNS”) that the maintenance contract would not be renewed for the third option year (beginning February 1, 2012) and that the contract would be terminated effective January 31, 2012. This non-renewal was preceded by a letter dated December 2, 2011 advising the Company of the U.S. Government’s intent to exercise the third option year. Although not stated in the notice provided by the U.S. Government, the Company believes the action is part of a budget reduction program being implemented by the DSNS.

The successful execution of the U.S. government contract program from the product build out in calendar year 2009 through the end of the second option year for maintenance services demonstrates the attractiveness of our integrated, full-service system that enables government agencies and commercial organizations to completely outsource the planning and execution of their emergency preparedness and disaster relief planning as it relates to medical waste handling and rapid response capabilities.

The Company believes the pace of regulation of sharps and unused dispensed medications disposal is gaining momentum at both the state and federal level. In December 2004, the U. S. Environmental Protection Agency (“EPA”) issued its new guidelines for the proper disposal of medical sharps, revising the previous guidance that advised patients to dispose of used syringes in the trash (see http://www.epa.gov/wastes/nonhaz/industrial/medical/med-govt.pdf). Additionally, in July 2006 both the states of California and Massachusetts passed legislation designed to mandate appropriate disposal of sharps waste necessary to protect the general public and workers from potential exposure to contagious diseases and health and safety risks. In April 2011, the U.S. Senate re-introduced a bill (S.725) which, if enacted, would provide for Medicare reimbursement, under part D, for the safe and effective disposal of used needles and syringes. To protect citizens and waste workers from needle stick injuries, eighteen states and the District of Columbia (covering 43% of the U.S. population) restrict or have introduced legislation to restrict discarding used sharps into household trash and twenty-nine states and the District of Columbia (covering 65% of the U.S. population) have enacted or introduced legislation to regulate the disposal of consumer unused medications to reduce pollution of the environment. As state and federal enforcement of these statutes increases, more companies will turn to solutions such as ours to help manage their medical waste and regulatory compliance. The Company believes it is well positioned to benefit given our strict adherence to established standards and extensive documentation and records.

The Company’s growth strategies are focused on the Retail, Pharmaceutical, Professional and Core Government markets. The Company also serves the Home Health Care, Assisted Living/Hospitality and Other markets. The Pharmaceutical market billings for the nine months ended March 31, 2012 increased $1.6 million over the prior year as a result of timing of customer orders including resupply orders for existing patient support programs and the launch during the period of three new patient support programs announced in August and October 2011. The combined new programs are expected to generate annual revenue in excess of $3.0 million once fully implemented after a six- to nine-month implementation period.

In October 2011, the Company announced the promotional program being offered for the Complete Needle™ Collection & Disposal System in support of National Diabetes Month sponsored by a leading global insulin manufacturer and the nation’s largest drugstore chain. Within this promotion program, the pharmaceutical manufacturer and the retail pharmacy in effect purchased the solutions from the Company and provided it at no cost to the user through rebates and redemption codes printed at the register. The Company believes this could serve as a model program for the country and that larger participation and sponsorship of the offering by other retail channels as well as additional drug and ancillary product manufacturers could follow. The Company also believes that similar sponsorship could be available for its TakeAway line of products for unused medications.

The Company currently has a cash balance of $16.6 million and no debt as of March 31, 2102. Under the Company’s Credit Agreement (“the Credit Agreement”) with Wells Fargo, National Association, the Company had no outstanding borrowings, $106 thousand in letters of credit outstanding, and $4.9 million of credit available. The Company received a Federal Tax refund of $0.5 million in April 2012 which related to the carryback of losses incurred thru June 30, 2011. This amount is included in Prepaid and Other Current Assets as of March 31, 2012.

RECENT DEVELOPMENTS

On May 2, 2012, the Company announced a marketing alliance with Daniels Sharpsmart Inc., which it believes creates a significant strategic advantage for both firms. The Company can now offer a convenient and cost effective waste management solution to customers and prospects with a combination of multi-site and multiple-sized facilities.

LIQUIDITY AND CAPITAL RESOURCES

Cash Flow

Cash and cash equivalents decreased by $1.7 million to $16.6 million at March 31, 2012 from $18.3 million at June 30, 2011. The decrease in cash and cash equivalents is primarily due to the timing of collections from orders related to billings in March 2012 and inventory buildup for new product lines (discussed below). The Company received a federal income tax refund of $0.5 million in April 2012.

Accounts receivable increased by $0.9 million to $4.0 million at March 31, 2012 from $3.1 million at June 30, 2011. The increase is due to due higher billings in March 2012.

Inventory increased by $0.7 million to $2.5 million at March 31, 2012 from $1.8 million at June 30, 2011. The increase in inventory is due to buildup of new product lines in preparation for new programs.

Working capital decreased $0.4 million to $19.8 million at March 31, 2012 from $20.2 million at June 30, 2011 as a result of the increase in current liabilities of $0.4 million due to timing of payments partially offset by the changes in cash and cash equivalents, accounts receivable and inventory (discussed above).

Property, plant and equipment, net decreased by $0.4 thousand to $4.9 million at March 31, 2012 from $5.3 million at June 30, 2011. The decrease in property and equipment is related to depreciation expense of $807 thousand, partially offset by capital expenditures of $362 thousand. The capital expenditures are attributable primarily to the purchase of, (i) computer equipment, new website project and custom software programming of $157 thousand, (ii) general leasehold improvements and warehouse equipment of $99 thousand, (iii) manufacturing and assembly equipment including molds, dies and printing plates of $81 thousand primarily for new product development and (iv) treatment facility improvement of $25 thousand.

Stockholders’ equity decreased by $0.2 to $25.7 million at March 31, 2012 from $25.9 million at June 30, 2011. This decrease is primarily attributable to a net loss for the nine months ended March 31, 2012 of $0.8 million. The impact was partially offset by (i) the effect on equity (credit) of non-cash stock based award expense of $0.6 million and (ii) the excess tax benefits from stock-based award activity of $61 thousand.

Off -Balance Sheet Arrangements

The Company entered into certain off-balance sheet arrangements in the ordinary course of business that result in risks not directly reflected in our balance sheets. The Company’s most significant off-balance sheet transactions include commitments associated with non-cancelable operating leases. The Company has other off-balance sheet obligations involving letters of credit.

The Company entered into non-cancelable operating leases for certain of our facility, vehicle and equipment needs. These leases allow us to conserve cash by paying a monthly lease rental fee for use of facilities, vehicles and equipment rather than purchasing them. At the end of the lease, the Company has no further obligation to the lessor. If we decide to cancel or terminate a lease before the end of its term, we would typically owe the lessor the remaining lease payments under the term of the lease.

Credit Facility

The Company estimates that the interest rate applicable to the borrowings under the Credit Agreement would be approximately 3.0% as of March 31, 2012.

Management believes that the Company’s current cash resources (cash on hand and cash generated from operations) along with its $5.0 million line of credit with Wells Fargo Bank will be sufficient to fund operations for the twelve months ending March 31, 2013. The Company received a federal income tax refund of $0.5 million in April 2012.

CRITICAL ACCOUNTING ESTIMATES

Revenue for the sale of the compliance and container is recognized upon delivery to the customer, at which time the customer takes title and assumes risk of ownership. Transportation revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s facility. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s facility. Treatment revenue is recognized upon the destruction or conversion and proof of receipt and treatment having been performed on the container. Since the transportation element and the treatment elements are undelivered services at the point of initial sale of the compliance and container, transportation and treatment revenue is deferred until the services are performed. The current and long-term portions of deferred revenues are determined through regression analysis and historical trends. Furthermore, through regression analysis of historical data, the Company has determined that a certain percentage of all container systems sold may not be returned. Accordingly, a portion of the transportation and treatment elements are recognized at the point of sale.

RECENTLY ISSUED ACCOUNTING STANDARDS

There are no recently issued accounting pronouncements that impact the Company’s condensed consolidated financial statements as of March 31, 2012.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company does not have exposure to significant financial market risk including commodity price risk, foreign currency exchange risk or interest rate risk. Management does not use derivative instruments. The Company has limited exposure to changes in interest rates due to its lack of indebtedness. The Company maintains a credit agreement under which we may borrow funds in the future. Currently, the Company does not foresee any borrowing needs.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

The Company maintains “disclosure controls and procedures”, as such term is defined in Rule 13a-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including, the Chief Executive Officer (“CEO”) and the Chief Financial Officer (“CFO”) as appropriate, to allow timely decisions regarding required disclosure.

As of March 31, 2012, the Company conducted an evaluation (the “Evaluation”), under the supervision and with the participation of the CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures (“Disclosure Controls”), pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based upon this Evaluation, the CEO and CFO concluded that our Disclosure Controls were effective as of March 31, 2012.

Changes in Internal Control over Financial Reporting

During the quarter ended March 31, 2012, there were no changes in the Company’s internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act), that have materially affected, or are reasonably likely to materially affect the Company’s internal control over financial reporting.

CEO and CFO Certifications

Appearing immediately following the Signatures section of this report are certifications of the CEO and the CFO. The Certifications are required in accordance with Section 302 of the Sarbanes-Oxley Act of 2002 (the Section 302 Certifications). This item of this quarterly report on Form 10-Q, which you are currently reading, is the information concerning the Evaluation referred to in the Section 302 Certification and this information should be read in conjunction with the Section 302 Certifications for a more complete understanding of the topics presented.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is involved in legal proceedings and litigation in the ordinary course of business. In the opinion of management, the outcome of such matters will not have a material adverse effect on the Company’s consolidated financial position or consolidated results of operations.

ITEM 1A. RISK FACTORS

Refer to Item 1A. Risk Factors in the Company’s annual report on Form 10-K for the year ended June 30, 2011 for the Company’s risk factors. During the quarter ended March 31, 2012, there have been no changes to the Company’s risk factors.

ITEM 6. EXHIBITS

(a)	Exhibits:

31.1	Certification of Chief Executive Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)

31.2	Certification of Chief Financial Officer in accordance with Section 302 of the Sarbanes-Oxley Act (filed herewith)

32.1	Certification of Chief Executive Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

32.2	Certification of Chief Financial Officer in accordance with Section 906 of the Sarbanes-Oxley Act (filed herewith)

101.INS	XBRL Instance Document (filed herewith)

101.SCH	XBRL Taxonomy Extension Schema Document (filed herewith)

101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document (filed herewith)

101.DEF	XBRL Taxonomy Extension Linkbase Document (filed herewith)

101.LAB	XBRL Taxonomy Extension Label Linkbase Document (filed herewith)

101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document (filed herewith)

ITEMS 2, 3, 4 AND 5 ARE NOT APPLICABLE AND HAVE BEEN OMITTED.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	REGISTRANT:
	SHARPS COMPLIANCE CORP.

Dated: May 3, 2012	By: /s/ DAVID P. TUSA
	David P. Tusa
	Chief Executive Officer and President
	(Principal Executive Officer)

Dated: May 3, 2012	By: /s/ DIANA P. DIAZ
	Diana P. Diaz
	Vice President and Chief Financial Officer
	(Principal Financial and Accounting Officer)

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

Sharps Compliance (SMED) 10-Q2012 Q3 Quarterly report

Content analysis